SCHEMBL6553846

SCHEMBL6553846

CC[Si](CC)(CC)Cc1cc(C(C)(C)C)c(S)c(C(C)(C)C)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 1/20 0.33
ALDH1A1 P00352 3/20 0.32
LMNA P02545 2/20 0.32
TSHR P16473 2/20 0.32
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.31
GMNN O75496 1/20 0.31
GABBR2 O75899 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
ALOX15 P16050 1/20 0.31
NFKB1 P19838 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2C19 P33261 1/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554132 0.85 GAA (0.32) HSPA5ALDH1A1LMNATSHRGAA
SCHEMBL5693108 0.82 GAA (0.31) HSPA5GAAKMT2A
SCHEMBL5692038 0.80
SCHEMBL5692042 0.80 ESR1 (0.34) HSPA5ALDH1A1LMNATSHRGAA
SCHEMBL5692525 0.78 ALDH1A1 (0.32) HSPA5ALDH1A1LMNATSHRGAA
SCHEMBL5692437 0.76 ALDH1A1 (0.31) ALDH1A1LMNATSHRGAAMEN1
SCHEMBL6553688 0.75 MEN1 (0.33) GAAMEN1KMT2A
SCHEMBL11853280 0.74 HSPA5 (0.39) HSPA5ALDH1A1LMNATSHRGAA
SCHEMBL7758054 0.71 NPC1 (0.42) HSPA5TSHRGAATP53CYP3A4
SCHEMBL5692121 0.70 NR1H2 (0.41) TSHRGAAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0732928-B1 METHOD OF LOWERING SERUM CHOLESTEROL LEVELS WITH 2,6-DI-ALKYL-4-SILYL-PHENOLS MERRELL PHARMA INC (US) 2004-12-22 EP disclosed
EP-1468693-A2 Use of 2,6-di -alkyl-4-silyl-phenols for treating diabetes mellitus MERRELL PHARMACEUTICALS INC. (US) 2004-10-20 EP disclosed
EP-1468692-A2 Use of 2,6-di-alkyl-4-silyl-phenols for treating xanthoma MERRELL PHARMACEUTICALS INC. (US) 2004-10-20 EP disclosed
CN-1092517-C Method for lowering serum cholesterol levels using 2, 6-dialkyl-4-silyl-phenols MERRELL DOW PHARMA (US) 2002-10-16 CN disclosed
US-5795876-A ANTIINFLAMMATORY AGENTS HOECHST MARION ROUSSSEL, INC. (US) 1998-08-18 US disclosed
CN-1140995-A Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols MERRELL DOW PHARMA (US) 1997-01-22 CN disclosed
US-5532400-A 2,6-di-alkyl-4-silyl-phenols as antiatheroscelerotic agents MERRELL PHARMACEUTICALS INC. (US) 1996-07-02 US disclosed
EP-0464852-B1 Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants MERRELL DOW PHARMA (US) 1996-03-20 EP disclosed
US-5155250-A 2,6-DI-ALKYL-4-SILYL-PHENOLS AS ANTIATHEROSCEROTIC AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1992-10-13 US disclosed
EP-0464852-A1 Novel 2,6-di-alkyl-4-silyl-phenols as antiatherosclerotic agents and as antioxidants MERRELL PHARMACEUTICALS INC. (US) 1992-01-08 EP disclosed